PMID- 15730851
OWN - NLM
STAT- MEDLINE
DCOM- 20050511
LR  - 20071114
IS  - 0301-472X (Print)
IS  - 0301-472X (Linking)
VI  - 33
IP  - 3
DP  - 2005 Mar
TI  - CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host 
      disease, or survival following myeloablative human leukocyte antigen-identical 
      peripheral blood allografting for hematologic malignancies.
PG  - 279-85
AB  - OBJECTIVES: Optimal granulocyte colony-stimulating factor-mobilized peripheral 
      blood progenitor cell (G-PBMC) graft compositions for myeloablative allogeneic 
      hematopoietic cell transplantation (AHCT) have not been identified. G-PBMC cell 
      contents were analyzed for influence on outcomes. PATIENTS AND METHODS: Human 
      leukocyte antigen(HLA)-identical related donor AHCT was used to treat 101 
      patients with hematologic malignancies at a single institution between 1995 and 
      2002. CD34+, CD3+, CD4+, and CD8+ cell doses were enumerated by flow cytometry 
      and evaluated by univariate analysis. RESULTS: Categorized by the median of cell 
      doses infused, no G-PBMC cell dose significantly correlated with neutrophil and 
      platelet engraftment. Incidence of grade II to IV acute graft-versus-host disease 
      (GVHD) was 24.6% (95% confidence interval [CI]: 15.9-33.3) and was not 
      significantly influenced by evaluated G-PBMC cell doses. With a median follow-up 
      time of 18 months for surviving patients, estimates for extensive chronic GVHD 
      was 43.8% (95% CI: 31.4-56.2), for freedom from progression was 69.5% (95% CI: 
      58.1-80.9), and for overall survival was 46.9% (95% CI: 35.5-58.3). CD34+, CD3+, 
      CD4+, and CD8+ cell doses were not significantly predictive of extensive chronic 
      GVHD, freedom from progression or overall survival. Additionally, comparing 
      patients receiving the upper versus lower 33rd percentiles of CD34+ cell dose, 
      associations with extensive chronic GVHD remained insignificant (p=0.21; relative 
      risk (RR)=1.7; 95% CI: 0.7-3.9). CONCLUSIONS: G-PBMC graft content does not 
      influence outcomes after myeloablative AHCT. In particular, no significant 
      association between extensive chronic GVHD was identified with any G-PBMC cell 
      dose, including CD34.
FAU - Cao, Thai M
AU  - Cao TM
AD  - Division of Blood and Marrow Transplantation, Department of Medicine, Stanford 
      University School of Medicine, Stanford, CA 94305-5623, USA.
FAU - Wong, Ruby M
AU  - Wong RM
FAU - Sheehan, Kevin
AU  - Sheehan K
FAU - Laport, Ginna G
AU  - Laport GG
FAU - Stockerl-Goldstein, Keith E
AU  - Stockerl-Goldstein KE
FAU - Johnston, Laura J
AU  - Johnston LJ
FAU - Shizuru, Judith A
AU  - Shizuru JA
FAU - Negrin, Robert S
AU  - Negrin RS
FAU - Lowsky, Robert
AU  - Lowsky R
LA  - eng
GR  - 2P01CA049605/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Exp Hematol
JT  - Experimental hematology
JID - 0402313
RN  - 0 (Antigens, Surface)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigens, Surface
MH  - Female
MH  - *Graft Survival
MH  - *Graft vs Host Disease
MH  - Hematologic Neoplasms/mortality/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Peripheral Blood Stem Cell Transplantation
MH  - Retrospective Studies
MH  - Transplantation Conditioning
MH  - Transplantation, Homologous
EDAT- 2005/02/26 09:00
MHDA- 2005/05/12 09:00
CRDT- 2005/02/26 09:00
PHST- 2004/10/21 00:00 [received]
PHST- 2004/12/03 00:00 [revised]
PHST- 2004/12/08 00:00 [accepted]
PHST- 2005/02/26 09:00 [pubmed]
PHST- 2005/05/12 09:00 [medline]
PHST- 2005/02/26 09:00 [entrez]
AID - S0301-472X(04)00444-8 [pii]
AID - 10.1016/j.exphem.2004.12.004 [doi]
PST - ppublish
SO  - Exp Hematol. 2005 Mar;33(3):279-85. doi: 10.1016/j.exphem.2004.12.004.